AIM IMMUNOTECH INC. Amortization of Debt Discount (Premium)
AIM IMMUNOTECH INC. (AIM) reported Amortization of Debt Discount (Premium) of $252.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2025-11-17
- AIM IMMUNOTECH INC. amortization of debt discount (premium) for the quarter ending 2025-09-30 was $69.00K.
- AIM IMMUNOTECH INC. amortization of debt discount (premium) for the quarter ending 2025-06-30 was $119.00K, a 39.59% decline year-over-year.
- AIM IMMUNOTECH INC. amortization of debt discount (premium) for the quarter ending 2025-03-31 was $64.00K, a 12.33% decline year-over-year.
- AIM IMMUNOTECH INC. amortization of debt discount (premium) for the quarter ending 2024-12-31 was $61.00K.
- AIM IMMUNOTECH INC. amortization of debt discount (premium) for fiscal 2024 was $293.00K.
- AIM IMMUNOTECH INC. amortization of debt discount (premium) for fiscal 2019 was $19.00K, a 84.03% decline from fiscal 2018.
- AIM IMMUNOTECH INC. amortization of debt discount (premium) for fiscal 2018 was $119.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 3 month as first filed | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 6 month as first filed | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 9 month as first filed | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|---|---|---|
| 2025-09-30 | $69.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $188.00K derived: sum of 2 quarters · filed 2025-11-17 | $252.00K 10-Q · filed 2025-11-17 | $313.00K derived: sum of 4 quarters · filed 2025-11-17 | |||
| 2025-06-30 | $119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $183.00K 10-Q · filed 2025-08-14 | $244.00K derived: sum of 3 quarters · filed 2025-08-14 | $206.00K derived: sum of 4 quarters · filed 2025-11-17 | |||
| 2025-03-31 | $64.00K 10-Q · filed 2025-05-15 | $125.00K derived: sum of 2 quarters · filed 2025-05-15 | $87.00K derived: sum of 3 quarters · filed 2025-11-17 | $284.00K derived: sum of 4 quarters · filed 2025-11-17 | |||
| 2024-12-31 | $61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $23.00K derived: sum of 2 quarters · filed 2025-11-17 | $220.00K derived: sum of 3 quarters · filed 2025-11-17 | $293.00K 10-K · filed 2025-03-27 | |||
| 2024-09-30 | -$38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $159.00K derived: sum of 2 quarters · filed 2025-11-17 | $232.00K 10-Q · filed 2025-11-17 | $226.00K 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $270.00K 10-Q · filed 2025-08-14 | $133.00K 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | $73.00K 10-Q · filed 2025-05-15 | $43.00K 10-Q · filed 2024-05-15 | |||||
| 2019-12-31 | $19.00K 10-K · filed 2020-03-30 | ||||||
| 2019-03-31 | $2.54K 10-Q · filed 2019-05-15 | -$2.38M derived: sum of 2 quarters · filed 2019-05-15 | $121.54K derived: sum of 3 quarters · filed 2019-05-15 | ||||
| 2018-12-31 | -$2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $119.00K derived: sum of 2 quarters · filed 2019-04-01 | $119.00K 10-K · filed 2019-04-01 | ||||
| 2018-09-30 | $2.50M 10-Q · filed 2018-11-14 | $2.50M 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |